Citadel Advisors’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $109M | Buy |
714,700
+270,500
| +61% | +$41.5M | 0.02% | 752 |
|
|
2025
Q4 | $61.2M | Buy |
444,200
+33,800
| +8% | +$4.43M | 0.01% | 1245 |
|
|
2025
Q3 | $52.6M | Buy |
410,400
+42,500
| +12% | +$5.19M | 0.01% | 1330 |
|
|
2025
Q2 | $44.5M | Buy |
367,900
+75,700
| +26% | +$8.53M | 0.01% | 1326 |
|
|
2025
Q1 | $32.6M | Sell |
292,200
-60,900
| -17% | -$6.48M | 0.01% | 1511 |
|
|
2024
Q4 | $34.4M | Sell |
353,100
-42,500
| -11% | -$4.53M | 0.01% | 1617 |
|
|
2024
Q3 | $45.5M | Buy |
395,600
+74,600
| +23% | +$8.46M | 0.01% | 1305 |
|
|
2024
Q2 | $34.2M | Sell |
321,000
-133,400
| -29% | -$13.4M | 0.01% | 1486 |
|
|
2024
Q1 | $44M | Sell |
454,400
-184,000
| -29% | -$18.9M | 0.01% | 1322 |
|
|
2023
Q4 | $64.5M | Buy |
638,400
+7,800
| +1% | +$753K | 0.01% | 985 |
|
|
2023
Q3 | $64.2M | Sell |
630,600
-200,900
| -24% | -$20.4M | 0.01% | 893 |
|
|
2023
Q2 | $83.9M | Sell |
831,500
-112,000
| -12% | -$11.2M | 0.02% | 718 |
|
|
2023
Q1 | $86.8M | Sell |
943,500
-682,400
| -42% | -$59.6M | 0.02% | 699 |
|
|
2022
Q4 | $148M | Buy |
1,625,900
+482,900
| +42% | +$40.7M | 0.03% | 465 |
|
|
2022
Q3 | $86.9M | Buy |
1,143,000
+455,500
| +66% | +$37.8M | 0.02% | 677 |
|
|
2022
Q2 | $58.1M | Sell |
687,500
-33,400
| -5% | -$2.93M | 0.01% | 904 |
|
|
2022
Q1 | $63.3M | Sell |
720,900
-64,300
| -8% | -$5.57M | 0.01% | 949 |
|
|
2021
Q4 | $68.7M | Buy |
785,200
+296,400
| +61% | +$24.6M | 0.01% | 930 |
|
|
2021
Q3 | $40M | Buy |
488,800
+139,600
| +40% | +$12.6M | 0.01% | 1302 |
|
|
2021
Q2 | $31.9M | Buy |
349,200
+25,300
| +8% | +$2.25M | 0.01% | 1547 |
|
|
2021
Q1 | $27.7M | Buy |
323,900
+6,300
| +2% | +$565K | 0.01% | 1598 |
|
|
2020
Q4 | $30M | Buy |
317,600
+164,000
| +107% | +$14.3M | 0.01% | 1391 |
|
|
2020
Q3 | $13.4M | Sell |
153,600
-233,000
| -60% | -$20.2M | ﹤0.01% | 1960 |
|
|
2020
Q2 | $33.8M | Buy |
386,600
+61,200
| +19% | +$5.28M | 0.01% | 1070 |
|
|
2020
Q1 | $26.8M | Buy |
325,400
+171,900
| +112% | +$15.3M | 0.01% | 1011 |
|
|
2019
Q4 | $14.5M | Sell |
153,500
-8,300
| -5% | -$745K | 0.01% | 1807 |
|
|
2019
Q3 | $14.1M | Buy |
161,800
+48,500
| +43% | +$4.35M | 0.01% | 1841 |
|
|
2019
Q2 | $10.3M | Buy |
113,300
+9,400
| +9% | +$796K | ﹤0.01% | 2138 |
|
|
2019
Q1 | $8.95M | Sell |
103,900
-91,512
| -47% | -$7.35M | ﹤0.01% | 2217 |
|
|
2018
Q4 | $15M | Buy |
195,412
+60,711
| +45% | +$4.73M | 0.01% | 1468 |
|
|
2018
Q3 | $10.4M | Buy |
134,701
+33,368
| +33% | +$2.47M | ﹤0.01% | 2052 |
|
|
2018
Q2 | $6.86M | Sell |
101,333
-66,402
| -40% | -$4.58M | ﹤0.01% | 2370 |
|
|
2018
Q1 | $12.2M | Buy |
167,735
+42,297
| +34% | +$3.22M | 0.01% | 1543 |
|
|
2017
Q4 | $9.44M | Buy |
125,438
+44,863
| +56% | +$3.38M | 0.01% | 1797 |
|
|
2017
Q3 | $6.2M | Sell |
80,575
-6,473
| -7% | -$489K | ﹤0.01% | 2072 |
|
|
2017
Q2 | $6.51M | Buy |
87,048
+14,173
| +19% | +$1M | 0.01% | 1833 |
|
|
2017
Q1 | $4.85M | Buy |
72,875
+35,824
| +97% | +$2.39M | ﹤0.01% | 2076 |
|
|
2016
Q4 | $2.42M | Sell |
37,051
-11,718
| -24% | -$760K | ﹤0.01% | 2733 |
|
|
2016
Q3 | $3.45M | Sell |
48,769
-7,143
| -13% | -$521K | ﹤0.01% | 2351 |
|
|
2016
Q2 | $4.13M | Buy |
+55,912
| New | +$3.86M | ﹤0.01% | 1987 |
|
Other funds holding NVS
Citadel Advisors's NVS Position: Q2 2025 in Review
Citadel Advisors sold out of Novartis (NVS) in Q2 2025, closing a stake of 1,067,586 shares — an estimated $120M sold.
Citadel Advisors first reported a position in NVS in Q3 2013 and held it in 44 quarters. The position peaked at $119M in Q1 2025. 1,383 funds tracked by Wall St. Rank hold NVS as of Q2 2025.
- Citadel Advisors reported no remaining Novartis position as of Q2 2025 after selling out during the quarter.
- Citadel Advisors sold 1,067,586 Novartis shares in Q2 2025, an estimated $120M.
- Citadel Advisors first reported a position in Novartis in Q3 2013 and held it in 44 quarters.
- Citadel Advisors's Novartis position peaked at $119M in Q1 2025.
- 1,383 funds tracked by Wall St. Rank held Novartis as of Q2 2025.
Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.